Emerging studies suggest Retatrutide , a dual activator targeting both incretin and GIP , could provide a promising development for weight treatment. Early patient investigations have shown substantial reductions in body tissue, potentially outperforming current obesity therapies . However , further assessment is necessary to thoroughly understand